Igawa M
Hinyokika Kiyo. 1986 Nov;32(11):1633-47.
The predictive value of grade, number of tumor and histology of mucosal biopsy for tumor recurrence, the course of carcinoma in situ and microinvasion of carcinoma in situ were examined. The Kaplan-Meier's method was used for the estimation of the recurrence-free rate in the patients who had undergone transurethral resection (TUR) and the logrank test for testing the significance of difference in recurrence-free rate. The 5-year recurrence-free rate was 32.2%. The recurrence-free rate was 51.0% after 40 months postoperatively in patients with a single tumor, 12.8% after 42 months postoperatively in those with multiple tumors. The patients with a single tumor had a significantly higher recurrence-free rate than those with multiple tumors (P less than 0.001). The recurrence-free rate was analyzed according to the grade of main tumor, but significantly difference was not present. The recurrence-free rate was 44.4% after 42 months postoperatively in patients with normal histology of mucosal biopsy and 9.5% after 34 months postoperatively in those with abnormal histology. The patients showing normal histology in mucosal biopsy had a significantly higher recurrence-free rate than those with abnormal findings (P less than 0.001). the recurrence-free rate at the same area of biopsy site was analyzed according to the histologies of 537 mucosal biopsies. The recurrence-free rate was 76.7% after 42 months post operatively in areas with a normal biopsy, 44.3% after 35 months postoperatively in those with abnormal histology and the difference was statistically significant (P less than 0.001). Of the 15 patients found to have carcinoma in situ, 4 were primary carcinoma in situ, 6 were associated with superficial papillary tumors and 5 were associated with invasive tumors. Thirteen of the 15 patients were alive and free of disease 18 to 42 months later. Two patients associated with invasive tumor died 5 and 18 months after transcatheter embolization of internal iliac arteries. Of the 13 patients who were found to have microinvasion of carcinoma in situ, 4 were not associated with visible tumor, 6 were associated with superficial papillary tumor and 3 were associated with invasive tumors. Nine of the 13 patients are alive and free of disease 7 to 53 months later. A patient without any visible tumor who was treated with TUR and intravesical chemotherapy died and three patients with invasive tumor died irrespective of the mode of treatment.(ABSTRACT TRUNCATED AT 400 WORDS)
研究了黏膜活检的分级、肿瘤数量及组织学对肿瘤复发、原位癌病程及原位癌微浸润的预测价值。采用Kaplan-Meier法估计经尿道切除术(TUR)患者的无复发生存率,并采用对数秩检验来检验无复发生存率差异的显著性。5年无复发生存率为32.2%。单发性肿瘤患者术后40个月时无复发生存率为51.0%,多发性肿瘤患者术后42个月时为12.8%。单发性肿瘤患者的无复发生存率显著高于多发性肿瘤患者(P<0.001)。根据主要肿瘤分级分析无复发生存率,但未发现显著差异。黏膜活检组织学正常的患者术后42个月时无复发生存率为44.4%,组织学异常的患者术后34个月时为9.5%。黏膜活检组织学表现正常的患者无复发生存率显著高于有异常发现的患者(P<0.001)。根据537例黏膜活检的组织学情况分析活检部位相同区域的无复发生存率。活检正常区域术后42个月时无复发生存率为76.7%,组织学异常区域术后35个月时为44.3%,差异有统计学意义(P<0.001)。在15例原位癌患者中,4例为原发性原位癌,6例与浅表乳头状肿瘤相关,5例与浸润性肿瘤相关。15例患者中有13例在18至42个月后存活且无疾病。2例与浸润性肿瘤相关的患者在髂内动脉经导管栓塞术后5个月和18个月死亡。在13例原位癌微浸润患者中,4例与可见肿瘤无关,6例与浅表乳头状肿瘤相关,3例与浸润性肿瘤相关。13例患者中有9例在7至53个月后存活且无疾病。1例接受TUR和膀胱内化疗且无可见肿瘤的患者死亡,3例浸润性肿瘤患者无论治疗方式如何均死亡。(摘要截选至400字)